Gilead Sciences, Inc.  

(Public, NASDAQ:GILD)   Watch this stock  
Find more results for GILD
0.00 (0.00%)
Pre-market: 107.18 +0.61 (0.57%)
Nov 25, 9:08AM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 85.95 - 123.37
Open     -
Vol / Avg. 1,530.00/9.77M
Mkt cap 153.59B
P/E 9.76
Div/yield 0.43/1.61
EPS 10.92
Shares 1.44B
Beta 0.83
Inst. own 82%
Feb 1, 2016
Q4 2015 Gilead Sciences Inc Earnings Release (Estimated) - 4:05PM EST - Add to calendar
Dec 1, 2015
Gilead Sciences Inc at Piper Jaffray Healthcare Conference - 9:30AM EST - Add to calendar
Dec 1, 2015
Gilead Sciences Inc at Nasdaq OMX Investor Program - 5:15AM EST - Add to calendar
Nov 10, 2015
Gilead Sciences Inc at Credit Suisse Healthcare Conference
Oct 27, 2015
Q3 2015 Gilead Sciences Inc Earnings Call - Webcast
Oct 27, 2015
Q3 2015 Gilead Sciences Inc Earnings Release
Sep 16, 2015
Gilead Sciences Inc at Morgan Stanley Healthcare Conference - Webcast
Sep 9, 2015
Gilead Sciences Inc at Robert W Baird and Co Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 55.36% 48.45%
Operating margin 67.33% 61.33%
EBITD margin - 65.55%
Return on average assets 41.02% 42.13%
Return on average equity 109.50% 90.32%
Employees 7,000 -
CDP Score - -


United States - Map
+1-650-5743000 (Phone)
+1-650-5789264 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha


Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Officers and directors

John C. Martin Ph.D. Chairman of the Board, Chief Executive Officer
Age: 63
Bio & Compensation  - Reuters
John F. Milligan Ph.D. President, Chief Operating Officer
Age: 54
Bio & Compensation  - Reuters
Robin L. Washington Chief Financial Officer, Executive Vice President
Age: 52
Bio & Compensation  - Reuters
Norbert W. Bischofberger Ph.D. Executive Vice President - Research and Development, Chief Scientific Officer
Age: 59
Bio & Compensation  - Reuters
Brett Pletcher Executive Vice President, General Counsel
Bio & Compensation  - Reuters
Gregg H. Alton Executive Vice President - Corporate and Medical Affairs
Age: 49
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Paul Rutherford Carter Executive Vice President - Commercial Operations
Age: 54
Bio & Compensation  - Reuters
Andrew Cheng M.D., Ph.D. Executive Vice President - HIV Therapeutics and Development Operations
Bio & Compensation  - Reuters
William A. Lee Ph.D. Executive Vice President - Research
Age: 56
Bio & Compensation  - Reuters
Taiyin Yang Ph.D. Executive Vice President - Pharmaceutical Development and Manufacturing
Age: 60
Bio & Compensation  - Reuters